Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort

Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L792 mutations, a non-covalent mechanism of osimertinib resistance, using Guardant360 cfDNA...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Exp Hematol Oncol
Main Authors: Fairclough, Stephen R., Kiedrowski, Lesli A., Lin, Jessica J., Zelichov, Ori, Tarcic, Gabi, Stinchcombe, Thomas E., Odegaard, Justin I., Lanman, Richard B., Shaw, Alice T., Nagy, Rebecca J.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Rapid Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6788107/
https://ncbi.nlm.nih.gov/pubmed/31632838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-019-0148-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados